肿瘤细胞治疗研究
英文原题：Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab for NSCLC: A Case Report.
免疫检查点抑制剂显著改善了NSCLC的预后。
免疫检查点抑制剂显著改善了NSCLC的预后。然而，已有多种免疫相关不良事件（irAEs）的报道。细胞因子释放综合征（CRS）是一种偶尔严重且危及生命的irAE。CRS是CAR-T 细胞治疗的主要irAE，也是抗程序性细胞死亡蛋白-1和程序性死亡配体1治疗的罕见irAE。因此，CRS在NSCLC中的报道较为罕见，但在抗程序性细胞死亡蛋白-1和抗程序性死亡配体1联合抗CTLA-4抗体获批后，CRS的报道正在增加。我们在此报告两例在NSCLC化疗中使用度伐利尤单抗联合替西木单抗后，对类固醇冲击治疗无效的CRS经托珠单抗治疗成功的病例。
Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threatening. CRS is a major irAE of the chimeric antigen receptor T-cell therapy and a rare irAE for anti-programmed cell death protein-1 and programmed death-ligand 1 therapy. Therefore, reports of CRS were rare in NSCLC, but after approval of anti-programmed cell death protein-1 and anti-programmed death-ligand 1 plus anti-CTLA-4 antibodies, reports of CRS are increasing. We, here, report two cases of successful tocilizumab treatment for steroid pulse-refractory CRS in chemotherapy with durvalumab plus tremelimumab for NSCLC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
